Share Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

Copy link

April 05, 2024

Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

13 minutes

Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.

...more